BIOLINERX
Careers | Contact Us
search

Drugs in Developement

BL-8040 Acute myeloid leukemia & other hematological cancers
BL-7010 Celiac Disease
BL-1040 AMI
BL-5010 Skin lesions
BL-7040 Inflammatory Bowel Disease
BL-8020 Hepatitis C (HCV)
BL-1020

Indication: Schizophrenia
Mode of Action: Dopamine antagonism and GABAergic activity
Stage of development: Phase II/III study discontinued following interim analysis; awaiting complete analysis of unblinded study data
Patent status: Patents granted or pending worldwide, 20-year expiration in 2033.

BL-1020 Overview
BL-1020 is an orally available, GABA enhanced antipsychotic that combines dopamine antagonism with GABAergic activity.
Following results of the CLARITY Phase II/III study, BioLineRx has discontinued the study and is now awaiting the completed analysis of the unblended study data.  
BL-1020 was invented by Prof. Abraham Nudelman, Prof. Abraham Weizmann, Dr. Irit Gilad and Dr. Ada Rephaeli.
BL-1020 is being developed by BioLineRx Ltd. under a worldwide exclusive license from Bar Ilan Research and Development Company Ltd. (BIRAD),and Ramot.
 
For more information: bd@BioLineRx.com